Apica Cardiovascular develops medical devices for cardiovascular care. Its focus is on systems and devices that enable direct implantation of aortic heart valves and mitral heart valves into the heart via the transapical route. These devices help treat structural heart disease and congestive heart failure.
The company targets three primary markets, exceeding $2.5 billion in total available market size: aortic valve replacement (AVR), mitral valve repair (MVR) and left ventricular assist devices (LVAD) implantation. Apica’s first commercial product was a device designed to facilitate transapical delivery of transcatheter heart valves in patients with severe aortic valve stenosis.
Note: In July 2014, Thoratec Corporation acquired Apica Cardiovascular for $35 million.